Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics

Kevin R Forward MD FRCP, Patricia A Franks PhD, Donald E Low MD FRCP, Robert Rennie PhD, Andrew E Simor MD FRCP and the Canadian Piperacillin/Tazobactam Study Group

OBJECTIVE: To compare the activity of piperacillin/tazobactam with that of other broad parenteral antibiotics against aerobic and facultative anaerobic blood culture isolates in a Canada-wide survey.

DESIGN: Fifty-eight laboratories in nine provinces each contributed up to 50 consecutive clinically significant aerobic and facultative anaerobic isolates for susceptibility testing.

SETTING: Participating hospitals included both tertiary care and community hospitals.

MATERIALS AND METHODS: Testing was performed in five regional centres by using the same microbroth dilution method, and results were interpreted according to National Committee for Clinical Laboratory Standards M7-A3 and M100-S5 guidelines.

RESULTS: Piperacillin/tazobactam and imipenem were both active against more than 99% of the 1616 strains of Enterobacteriaceae species tested. The minimum inhibitory concentration of 90% of isolates (MIC90) of all Enterobacteriaceae species was 2 mg/L for piperacillin/tazobactam compared with 64 mg/L for piperacillin alone. Seventeen per cent of strains of Enterobacteriaceae species were susceptible to piperacillin/tazobactam but resistant to piperacillin. Piperacillin/tazobactam was highly active against Pseudomonas aeruginosa, inhibiting 99.1% of strains. MIC90 was 8 mg/L. Nine per cent of P aeruginosa strains were not susceptible to imipenem. Most of these strains had a MIC of 8 mg/L, which falls in the intermediate category. Ninety-six per cent of P aeruginosa were susceptible to ciprofloxacin and 97.3% to tobramycin. Ninety-six per cent of strains of Actinobacter species were susceptible to piperacillin/tazobactam, whereas only 76% of strains were susceptible to piperacillin alone. Overall, piperacillin/tazobactam was the most active agent tested, 98% of all strains were susceptible, followed closely by imipenem, to which 97.8% of strains were susceptible.

CONCLUSIONS: Aerobic blood culture isolates from Canadian centres continue to be highly susceptible to a variety of antibiotics. The broad spectrum of activity of piperacillin/tazobactam suggests that this combination should be considered for empirical treatment of sepsis while awaiting results of cultures and susceptibility testing.

Key Words: Antibiotic resistance, Piperacillin, Tazobactam, Susceptibility survey
Enquête pancanadienne sur la résistance de 2 747 isolats d’hémocultures aérobies à l’endroit du pipéracilline/tazobactam et d’autres antibiotiques

OBJECTIF : Comparer l’activité du pipéracilline/tazobactam à celle d’autres antibiotiques parentéraux à large spectre contre des isolats d’hémocultures aérobies et anaérobies facultatifs dans le cadre d’une enquête pancanadienne.

MODELE : Cinquante-huit laboratoires de neuf provinces ont chacun fourni jusqu’à 50 isolats aérobies et anaérobies facultatifs cliniquement significatifs aux fins d’expériences de sensibilité.

CONTEXTE : Les hôpitaux participants étaient notamment des centres de soins tertiaires et communautaires.

MATÉRIEL ET MÉTHODES : Les épreuves ont été effectuées dans cinq centres régionaux au moyen, des mêmes méthodes de microdilution et les résultats ont été interprétés conformément aux directives M7-A3 et M100-S5 du NCCLS (National Committee for Clinical Laboratory Standards).

RÉSULTATS : Le pipéracilline/tazobactam et l’imipéném ont tous deux été efficaces contre plus de 99 % des 1 616 souches d’Enterobacteriaceae testées. Les concentrations inhibitrices minimum de 90 % des isolats (CMI90) de tous les Enterobacteriaceae ont été de 2 mg/L pour le pipéracilline/tazobactam contre 64 mg/L pour la pipéracilline seule. Seize pour cent des souches d’Enterobacteriaceae se sont révélées sensibles au pipéracilline/tazobactam, mais résistantes à la pipéracilline. Le pipéracilline/tazobactam a été très efficace contre Pseudomonas aeruginosa, inhibant 99,1 % des souches. La CMI90 a été de 8 mg/L; 9 % des souches de P. aeruginosa se sont révélées insensibles à l’imipéném. La plupart de ces souches avaient des CMI de 8 mg/L, ce qui les classe dans la catégorie de résistance intermédiaire. Quatre-vingt-dix-sept pour cent des isolats de P. aeruginosa ont été sensibles à la ciprofloxacine, 97,3 % à la tobramycine. Quatre-vingt-seize pour cent des souches d’Acinetobacter ont été sensibles au pipéracilline/tazobactam, alors que 76 % seulement des souches étaient sensibles à la pipéracilline seule. Globalement, le pipéracilline/tazobactam a été l’agent le plus actif testé. Quatre-vingt-dix-huit pour cent de toutes les souches ont été sensibles, suivi de près par l’imipéném auquel 97,8 % des souches ont été sensibles.

CONCLUSIONS : Les isolats d’hémocultures aérobies provenant de centres canadiens continuent d’être très sensibles à divers antibiotiques. Le vaste spectre d’activité du pipéracilline/tazobactam donne à penser que cette association médicamenteuse est à envisager en traitement empirique de la septicémie en attendant les résultats des cultures et des antibiogrammes.

Piperacilline/tazobactam is the most recent of a number of beta-lactam/beta-lactamase inhibitor combinations to become available to Canadian physicians. The combination offers a number of advantages over previously marketed compounds. Piperacillin has a broader spectrum of activity than either the amino or carboxy penicillins, and tazobactam is a potent inhibitor of both chromosomally mediated and plasmid-mediated beta-lactamases (1,2,3).

Numerous clinical trials have demonstrated the efficacy of piperacillin/tazobactam in the treatment of a variety of infections, including intra-abdominal infections, skin and skin structure infections, pelvic infections in women, pneumonia and fever in neutropenic patients undergoing chemotherapy for both solid and hematological malignancies (4-13). Non-comparative trials have also evaluated the efficacy of piperacillin/tazobactam with or without an aminoglycoside for the treatment of bacteremia (14,15).

We conducted a prospective study of susceptibilities of blood culture isolates collected in 1995 from 58 sites across Canada to determine the prevalence of resistance to commonly used broad spectrum antibiotics, including piperacillin/tazobactam. Such data may help to establish the degree of confidence with which single agents may be used to treat serious bacteremic infections.

MATERIALS AND METHODS

Strains: Fifty-eight teaching and community hospitals from nine Canadian provinces participated in the evaluation. In most cases, 50 consecutive aerobic cultures were collected, beginning in February 1995. A few smaller centres fell short of this goal. Methicillin-resistant Staphylococcus species and anaerobes were not included. Potential contaminants, such as coagulase-negative Staphylococcus species and viridans streptococci, were submitted only if recovered on three different occasions from the same patient within one week. Only one strain from each species was submitted per patient.

Methods: Broth microdilution susceptibility studies were performed with 96-well microtitre plates containing serial twofold dilutions of study antibiotics. Panels were prepared by Sensititre (AccuMed International Inc, Ohio) and distributed to each of five regional testing centres. Organisms were speciated in their originating laboratory by using standard methods. Non-fastidious organisms were tested in accordance with National Committee for Clinical Laboratory Standards (NCCLS) guidelines (NCCLS M7-A3 and M100-S5) (16,17). Inocula were prepared by directly inoculating four to five colonies of an overnight culture of the organism incubated at 35 to 37°C into demineralized water to produce a suspension corresponding to a 0.5 McFarland standard. Ten microlitres of inoculum was suspended in 10 mL of cation-supplemented Mueller Hinton broth. Fifty microlitres of the resulting suspension was transferred to each well of the microtitre plates, which were then incubated aerobically at 34 to 36°C for 18 h.

For susceptibility testing of Strepococcus pneumoniae, the inoculum was prepared in Mueller Hinton broth from overnight growth on 5% sheep blood agar. After mixing, 100 µL of inoculum was added to 10 mL of cation-supplemented Mueller Hinton broth with added 2% to 5% lysed horse blood (PML Microbiological, Oregon). One hundred microlitres was inoculated to each well of the microtitre panel with an autoinoculator. Plates were incubated aerobically at 35°C for 20 to 24 h.

Susceptibility testing for streptococci other than S pneumoniae was performed as for S pneumoniae except that only 10 µL was added to 10 mL of Mueller Hinton broth and 50 µL was added to each well.

For Haemophilus influenzae, the inoculum was prepared in...
Mueller Hinton broth from isolated colonies on chocolate agar. Fifty microlitres of inoculum was transferred to 10 mL of *Haemophilus* species test medium broth (HTM) (BBL, Becton Dickinson and Company, Maryland). One hundred microlitres of HTM was added to each well. Plates were incubated at 35°C in carbon dioxide for 20 to 24 h.

All testing was performed using the same lot number of panels, *Haemophilus* species test medium and cation-supplemented Mueller Hinton broth. American type culture collection (ATCC) organisms were tested as appropriate, with each batch of organisms run against both Gram-positive and Gram-negative microtitre panels – *Staphylococcus aureus* ATCC 29213, *Enterococcus faecalis* ATCC 29212 *Escherichia coli* ATCC 25922, *E. coli* ATCC 35218 and *Pseudomonas aeruginosa* ATCC 27853.

**RESULTS**

Of the 2747 blood culture isolates tested, piperacillin/tazobactam was most active, inhibiting 98% of strains, followed closely by imipenem, which inhibited 97.8% of strains (Table 1). Ceftazidime, ceftriaxone, ciprofloxacin and ticarcillin-clavulanate each inhibited over 90% of strains. Overall, the proportion of strains susceptible to third-generation cephalosporins and ciprofloxacin was lower than this percentage, primarily because of their intrinsic inactivity against enterococci, which comprised 160 of 2747 isolates. Against the 1611 strains of *Enterobacteriaceae* species tested, piperacillin/tazobactam was second only to imipenem in terms of the percentage of strains susceptible; only 0.2% of strains were resistant (Table 2). The minimum inhibitory concentration of 90% of isolates (MIC90) of *Enterobacteriaceae* species was 2 mg/L compared with 64 mg/L for piperacillin alone. Seventeen per cent of *Enterobacteriaceae* species were susceptible to piperacillin/tazobactam but resistant to piperacillin. *Enterobacteriaceae* species remained highly susceptible to all agents tested, with the exception of piperacillin and cefoxitin, which inhibited 82% and 81% of strains, respectively. Figure 1 compares piperacillin/tazobactam with piperacillin MICs against strains of *Enterobacteriaceae* species, *E. coli, Enterobacter cloacae* and *Acinetobacter* species. The majority of strains had lower piperacillin MICs in the presence of tazobactam than with piperacillin alone.

**TABLE 1**

| Antibiotic | % Susceptible |
|------------|---------------|
| Piperacillin-tazobactam | 98.0 |
| Piperacillin    | 87.5 |
| Imipenem         | 97.8 |
| Ceftazidime     | 91.8 |
| Ciprofloxacin   | 92.8 |
| Ticarcillin-clavulanate | 90.8 |
| Ceftriaxone     | 91.5 |

Piperacillin/tazobactam was the most active agent against *P. aeruginosa*, inhibiting 99.1% of strains; MIC90 was 8 mg/L. Ninety-one per cent of strains were susceptible to imipenem and 8% had a MIC of 8 mg/L, which fell into the intermediate category. Of the 111 strains of *P. aeruginosa* tested, 97.3% of

---

**Figure 1** Comparison of the minimal inhibitory concentration (MIC) of piperacillin alone with that of piperacillin/tazobactam (8:1 ratio)
**TABLE 2**
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates

| Organism (number of strains) | Antibiotic           | Range (mg/L) | MIC<sub>50</sub> (mg/L) | MIC<sub>90</sub> (mg/L) | %S   | %I   | %R   |
|------------------------------|----------------------|--------------|--------------------------|--------------------------|------|------|------|
| *Escherichia coli* (805)     | Piperacillin/tazobactam | 0.25 - 256   | 0.5                      | 1                        | 99.9 | 0    | 0.1  |
|                              | Piperacillin          | 0.25 - 256   | 1                        | 128                      | 77.8 | 8.9  | 13.3 |
|                              | Imipenem              | 0.12 - 8     | 0.12                     | 0.12                     | 99.9 | 0.1  | 0    |
|                              | Ceftazidime           | 0.12 - 64    | 0.25                     | 0.5                      | 97.1 | 0.6  | 2.2  |
|                              | Ciprofloxacin         | 0.12 - 8     | 0.12                     | 0.12                     | 98.1 | 0.4  | 1.5  |
|                              | Tobramycin            | 0.12 - 32    | 0.25                     | 1                        | 98.3 | 1    | 0.7  |
|                              | Gentamicin            | 0.12 - 32    | 0.25                     | 0.5                      | 97.4 | 1.1  | 1.5  |
|                              | Ticarcillin-clavulanate | 0.25 - 128  | 1                        | 8                        | 98.4 | 1.5  | 0.1  |
|                              | Ceftiraxone           | 0.25 - 128   | 0.25                     | 0.5                      | 97.4 | 0.9  | 1.7  |
|                              | Cefotaxime            | 0.25 - 128   | 0.25                     | 0.5                      | 97.5 | 0.9  | 1.6  |
|                              | Cefoxitin             | 0.25 - 64    | 2                        | 16                       | 88.6 | 3.7  | 7.7  |
| *Klebsiella pneumoniae* (152)| Piperacillin/tazobactam | 0.25 - 16    | 1                        | 4                        | 100  | 0    | 0    |
|                              | Piperacillin          | 0.5 - 64     | 4                        | 8                        | 94.7 | 5.3  | 0    |
|                              | Imipenem              | 0.12 - 8     | 0.12                     | 0.25                     | 99.3 | 0.7  | 0    |
|                              | Ceftazidime           | 0.25 - 64    | 0.25                     | 1                        | 96.7 | 1.3  | 2    |
|                              | Ciprofloxacin         | 0.12 - 4     | 0.12                     | 0.12                     | 98.7 | 0.7  | 0.7  |
|                              | Tobramycin            | 0.12 - 16    | 0.25                     | 0.5                      | 98   | 0.7  | 1.3  |
|                              | Gentamicin            | 0.12 - 32    | 0.25                     | 0.5                      | 97.4 | 0.7  | 2    |
|                              | Ticarcillin-clavulanate | 0.25 - 128  | 1                        | 4                        | 97.4 | 1.3  | 1.3  |
|                              | Ceftiraxone           | 0.25 - 128   | 0.25                     | 1                        | 98   | 1.3  | 0.7  |
|                              | Cefotaxime            | 0.25 - 64    | 0.25                     | 0.5                      | 97.4 | 2    | 0.7  |
|                              | Cefoxitin             | 0.5 - 64     | 2                        | 16                       | 86.8 | 3.9  | 9.2  |
| *Klebsiella oxytoca* (48)    | Piperacillin/tazobactam | 0.25 - 16    | 0.5                      | 2                        | 100  | 0    | 0    |
|                              | Piperacillin          | 1 - 256      | 4                        | 8                        | 95.8 | 2.1  | 2.1  |
|                              | Imipenem              | 0.12 - 0.5   | 0.12                     | 0.25                     | 100  | 0    | 0    |
|                              | Ceftazidime           | 0.25 - 16    | 0.25                     | 4                        | 97.9 | 2.1  | 0    |
|                              | Ciprofloxacin         | 0.12 - 1     | 0.12                     | 0.12                     | 100  | 0    | 0    |
|                              | Tobramycin            | 0.12 - 2     | 0.25                     | 0.5                      | 100  | 0    | 0    |
|                              | Gentamicin            | 0.12 - 4     | 0.25                     | 0.5                      | 100  | 0    | 0    |
|                              | Ticarcillin-clavulanate | 0.25 - 64   | 1                        | 8                        | 97.9 | 2.1  | 0    |
|                              | Ceftiraxone           | 0.25 - 64    | 0.25                     | 2                        | 95.8 | 2.1  | 2.1  |
|                              | Cefotaxime            | 0.25 - 64    | 0.25                     | 1                        | 97.9 | 0    | 2.1  |
|                              | Cefoxitin             | 0.5 - 64     | 1                        | 16                       | 89.6 | 2.1  | 8.3  |
| *Citrobacter freundii* (9)  | Piperacillin/tazobactam | 0.5 - 8      | 2                        | 8                        | 100  | 0    | 0    |
|                              | Piperacillin          | 0.5 - 64     | 2                        | 64                       | 77.8 | 22.2 | 0    |
|                              | Imipenem              | 0.12 - 0.5   | 0.12                     | 0.5                      | 100  | 0    | 0    |
|                              | Ceftazidime           | 0.25 - 32    | 0.25                     | 32                       | 88.9 | 0    | 11.1 |
|                              | Ciprofloxacin         | 0.12 - 1     | 0.12                     | 1                        | 100  | 0    | 0    |
|                              | Tobramycin            | 0.12 - 0.5   | 0.25                     | 0.5                      | 100  | 0    | 0    |
|                              | Gentamicin            | 0.12 - 1     | 0.25                     | 1                        | 100  | 0    | 0    |
|                              | Ticarcillin-clavulanate | 0.5 - 64    | 2                        | 64                       | 77.8 | 22.2 | 0    |

Continued on next page
TABLE 2 continued
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates

| Organism         | Antibiotic          | Range (mg/L) | MIC<sub>50</sub> (mg/L) | MIC<sub>90</sub> (mg/L) | %S | %I | %R |
|------------------|---------------------|--------------|-------------------------|-------------------------|----|----|----|
| C freundii       | Ceftriaxone         | 0.25 - 32    | 0.25                    | 32                      | 88.9  | 11.1  | 0  |
|                  | Cefotaxime          | 0.25 - 16    | 0.25                    | 16                      | 88.9  | 11.1  | 0  |
|                  | Cefoxitin           | 2 - 64       | 32                      | 64                      | 22.2  | 11.1  | 66.7 |
| Proteus mirabilis| Piperacillin/tazobactam | 0.25 - 1    | 0.25                    | 0.5                     | 100   | 0    | 0  |
|                  | Piperacillin        | 0.25 - 8     | 0.25                    | 1                       | 100   | 0    | 0  |
|                  | Imipenem            | 0.12 - 4     | 0.5                     | 1                       | 100   | 0    | 0  |
|                  | Cefazidime          | 0.25 - 1     | 0.25                    | 0.25                    | 100   | 0    | 0  |
|                  | Ciprofloxacin       | 0.12 - 0.25  | 0.12                    | 0.12                    | 100   | 0    | 0  |
|                  | Tobramycin          | 0.12 - 16    | 0.5                     | 1                       | 90.2  | 4.9  | 4.9 |
|                  | Gentamicin          | 0.12 - 16    | 0.5                     | 1                       | 90.2  | 2.4  | 7.3 |
|                  | Ticarcillin-clavulanate | 0.25 - 8    | 0.25                    | 1                       | 100   | 0    | 0  |
|                  | Ceftriaxone         | 0.25 - 2     | 0.25                    | 0.25                    | 100   | 0    | 0  |
|                  | Cefotaxime          | 0.25 - 1     | 0.25                    | 0.25                    | 100   | 0    | 0  |
|                  | Cefoxitin           | 1 - 16       | 2                       | 2                       | 97.6  | 2.4  | 0  |
| Enterobacter cloaceae (77) | Piperacillin/tazobactam | 0.25 - 256  | 1                       | 32                      | 89.6  | 9.1  | 1.3 |
|                  | Piperacillin        | 0.5 - 256    | 2                       | 128                     | 76.6  | 10.4 | 13  |
|                  | Imipenem            | 0.12 - 4     | 0.12                    | 0.25                    | 100   | 0    | 0  |
|                  | Cefazidime          | 0.25 - 64    | 0.25                    | 64                      | 75.3  | 2.6  | 22.1 |
|                  | Ciprofloxacin       | 0.12 - 8     | 0.12                    | 0.25                    | 96.1  | 1.3  | 2.6 |
|                  | Tobramycin          | 0.12 - 16    | 0.25                    | 0.5                     | 97.4  | 0    | 2.6 |
|                  | Gentamicin          | 0.12 - 8     | 0.12                    | 0.5                     | 97.4  | 2.6  | 0  |
|                  | Ticarcillin-clavulanate | 0.25 - 256  | 2                       | 128                     | 74    | 11.7 | 14.3 |
|                  | Ceftriaxone         | 0.25 - 128   | 0.25                    | 128                     | 74    | 6.5  | 19.5 |
|                  | Cefotaxime          | 0.25 - 128   | 0.25                    | 128                     | 74    | 7.8  | 18.2 |
|                  | Cefoxitin           | 2 - 64       | 64                      | 64                      | 6.5   | 3.9  | 89.6 |
| Enterobacter aerogenes (16) | Piperacillin/tazobactam | 0.25 - 32   | 2                       | 32                      | 87.5  | 12.5 | 0  |
|                  | Piperacillin        | 0.25 - 64    | 4                       | 64                      | 75    | 25   | 0  |
|                  | Imipenem            | 0.12 - 0.5   | 0.12                    | 0.5                     | 100   | 0    | 0  |
|                  | Cefazidime          | 0.25 - 64    | 0.25                    | 32                      | 62.5  | 12.5 | 25  |
|                  | Ciprofloxacin       | 0.12 - 2     | 0.12                    | 0.5                     | 93.8  | 6.3  | 0  |
|                  | Tobramycin          | 0.12 - 8     | 0.25                    | 2                       | 93.8  | 6.3  | 0  |
|                  | Gentamicin          | 0.12 - 8     | 0.25                    | 2                       | 93.8  | 6.3  | 0  |
|                  | Ticarcillin-clavulanate | 0.5 - 64    | 8                       | 64                      | 68.8  | 31.3 | 0  |
|                  | Ceftriaxone         | 0.25 - 128   | 0.25                    | 16                      | 75    | 18.8 | 6.3 |
|                  | Cefotaxime          | 0.25 - 128   | 0.25                    | 8                       | 93.8  | 0    | 6.3 |
|                  | Cefoxitin           | 1 - 64       | 64                      | 64                      | 6.3   | 12.5 | 81.3 |
| Serratia marcescens (22) | Piperacillin/tazobactam | 0.25 - 16   | 1                       | 2                       | 100   | 0    | 0  |
|                  | Piperacillin        | 0.25 - 16    | 2                       | 16                      | 100   | 0    | 0  |
|                  | Imipenem            | 0.12 - 32    | 0.25                    | 0.5                     | 95.5  | 0    | 4.5 |
|                  | Cefazidime          | 0.25 - 1     | 0.25                    | 0.5                     | 100   | 0    | 0  |
|                  | Ciprofloxacin       | 0.12 - 2     | 0.12                    | 0.12                    | 95.5  | 4.5  | 0  |

Can J Infect Dis Vol 9 No 1 January/February 1998
### TABLE 2 continued
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates

| Organism (number of strains) | Antibiotic | Range (mg/L) | MIC<sub>50</sub> (mg/L) | MIC<sub>90</sub> (mg/L) | %S | %I | %R |
|-----------------------------|------------|--------------|--------------------------|-------------------------|----|----|----|
| *S marsescens*              | Tobramycin | 0.12 - 8     | 0.5                      | 4                       | 95.5 | 4.5 | 0  |
|                             | Gentamicin | 0.12 - 8     | 0.25                     | 1                       | 95.5 | 4.5 | 0  |
|                             | Ticarcillin-clavulanate | 1 - 128 | 4                      | 32                      | 86.4 | 4.5 | 9.1 |
|                             | Ceftriaxone | 0.25 - 8     | 0.25                     | 2                       | 100  | 0   | 0  |
|                             | Cefotaxime  | 0.25 - 16    | 0.25                     | 8                       | 90.9 | 9.1 | 0  |
|                             | Cefoxitin   | 4 - 64       | 16                       | 64                      | 45.5 | 22.7 | 31.8 |
| Other *Enterobacteriaceae* (39) | Piperacillin/tazobactam | 0.25 - 16 | 1                      | 4                       | 100  | 0   | 0  |
|                             | Piperacillin | 0.5 - 256   | 1                       | 64                      | 89.2 | 2.7 | 8.1 |
|                             | Imipenem    | 0.12 - 0.25  | 0.12                     | 0.12                    | 100  | 0   | 0  |
|                             | Ceftazidime | 0.25 - 64    | 0.25                     | 0.5                     | 94.6 | 0   | 5.4 |
|                             | Ciprofloxacin | 0.12 - 0.25 | 0.12                     | 0.12                    | 100  | 0   | 0  |
|                             | Tobramycin  | 0.12 - 1     | 0.25                     | 0.5                     | 100  | 0   | 0  |
|                             | Gentamicin  | 0.12 - 0.5   | 0.12                     | 0.5                     | 100  | 0   | 0  |
|                             | Ticarcillin-clavulanate | 0.25 - 32 | 1                      | 8                       | 94.6 | 5.4 | 0  |
|                             | Ceftriaxone | 0.25 - 128   | 0.25                     | 8                       | 94.6 | 0   | 5.4 |
|                             | Cefotaxime  | 0.25 - 128   | 0.25                     | 2                       | 94.6 | 2.7 | 2.7 |
|                             | Cefoxitin   | 0.25 - 64    | 1                       | 4                       | 91.9 | 0   | 8.1 |
| *Morganella morganii* (7)   | Piperacillin/tazobactam | 0.25 - 4   | 0.25                    | 4                       | 100  | 0   | 0  |
|                             | Piperacillin | 0.25 - 4     | 1                       | 4                       | 100  | 0   | 0  |
|                             | Imipenem    | 0.12 - 2     | 1                       | 2                       | 100  | 0   | 0  |
|                             | Ceftazidime | 0.25 - 64    | 0.25                     | 64                      | 85.7 | 0   | 14.3 |
|                             | Ciprofloxacin | 0.12 - 8    | 0.12                     | 8                       | 85.7 | 0   | 14.3 |
|                             | Tobramycin  | 0.25 - 16    | 0.5                      | 16                      | 85.7 | 0   | 14.3 |
|                             | Gentamicin  | 0.25 - 2     | 0.5                      | 2                       | 100  | 0   | 0  |
|                             | Ticarcillin-clavulanate | 0.25 - 4  | 2                       | 4                       | 100  | 0   | 0  |
|                             | Ceftriaxone | 0.25 - 64    | 0.25                     | 64                      | 85.7 | 0   | 14.3 |
|                             | Cefotaxime  | 0.25 - 16    | 0.25                     | 16                      | 85.7 | 14.3 | 0  |
|                             | Cefoxitin   | 4 - 64       | 4                       | 64                      | 85.7 | 0   | 14.3 |
| *Pseudomonas aeruginosa* (111) | Piperacillin/tazobactam | 0.5 - 256 | 2                       | 8                       | 99.1 | 0   | 0.9 |
|                             | Piperacillin | 0.5 - 256    | 4                       | 16                      | 96.4 | 0   | 3.6 |
|                             | Imipenem    | 0.12 - 16    | 1                       | 4                       | 91   | 8.1 | 0.9 |
|                             | Ceftazidime | 0.25 - 64    | 1                       | 16                      | 89.2 | 6.3 | 4.5 |
|                             | Ciprofloxacin | 0.12 - 8    | 0.12                     | 0.25                    | 97.3 | 0   | 2.7 |
|                             | Tobramycin  | 0.12 - 32    | 0.25                     | 1                       | 97.3 | 0.9 | 2.7 |
|                             | Gentamicin  | 0.12 - 32    | 0.5                      | 4                       | 95.5 | 1.8 | 2.7 |
|                             | Ticarcillin-clavulanate | 0.5 - 256 | 16                      | 64                      | 93.6 | 0   | 6.4 |
| *Pseudomonas species* (5)   | Piperacillin/tazobactam | 1 - 4     | 2                       | 4                       | 100  | 0   | 0  |
|                             | Piperacillin | 4 - 256      | 4                       | 256                     | 80   | 0   | 20  |
|                             | Imipenem    | 0.25 - 1     | 0.5                      | 1                       | 100  | 0   | 0  |
|                             | Ceftazidime | 1 - 64       | 16                      | 64                      | 20   | 60  | 20  |
|                             | Ciprofloxacin | 0.12 - 4    | 0.12                     | 4                       | 80   | 0   | 20  |

Continued on next page
TABLE 2 continued
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates

| Organism (number of strains) | Antibiotic     | Range (mg/L) | MIC<sub>50</sub> (mg/L) | MIC<sub>90</sub> (mg/L) | % S | % I | % R |
|------------------------------|----------------|--------------|--------------------------|--------------------------|-----|----|-----|
| *Pseudomonas* species        | Tobramycin     | 0.25 - 1     | 0.5                      | 1                        | 100 | 0  | 0   |
|                              | Gentamicin     | 0.12 - 2     | 0.5                      | 2                        | 100 | 0  | 0   |
|                              | Ticarcillin-clavulanate | 0.25 - 256 | 64                       | 256                      | 20  | 40 | 40  |
|                              | Ceftriaxone    | 2 - 128      | 8                        | 128                      | 60  | 0  | 40  |
|                              | Cefotaxime     | 4 - 128      | 8                        | 128                      | 60  | 0  | 20  |
|                              | Cefoxitin      | 8 - 64       | 64                       | 64                       | 20  | 0  | 80  |
| *Acinetobacter* species (25) | Piperacillin/tazobactam | 0.25 - 32 | 0.5                      | 8                        | 96  | 4  | 0   |
|                              | Piperacillin   | 0.5 - 256    | 8                        | 256                      | 76  | 12 | 12  |
|                              | Imipenem       | 0.12 - 32    | 0.12                     | 0.5                      | 96  | 0  | 4   |
|                              | Ceftazidime    | 0.25 - 64    | 2                        | 8                        | 92  | 0  | 8   |
|                              | Ciprofloxacin  | 0.12 - 8     | 0.12                     | 8                        | 88  | 0  | 12  |
|                              | Tobramycin     | 0.12 - 32    | 0.25                     | 16                       | 76  | 4  | 20  |
|                              | Gentamicin     | 0.12 - 32    | 0.5                      | 32                       | 76  | 4  | 20  |
|                              | Ticarcillin-clavulanate | 0.25 - 128 | 4                        | 64                       | 84  | 12 | 4   |
|                              | Ceftriaxone    | 0.25 - 128   | 8                        | 64                       | 68  | 20 | 12  |
|                              | Cefotaxime     | 0.25 - 64    | 4                        | 64                       | 70.8| 16.7| 12.5|
|                              | Cefoxitin      | 1 - 64       | 64                       | 64                       | 28  | 4  | 68  |
| *Stenotrophomonas maltophilia* (13) | Piperacillin/tazobactam | 8 - 256 | 8                        | 256                      | 61.5| 0  | 38.5|
|                              | Piperacillin   | 8 - 256      | 32                       | 256                      | 38.5| 23.1| 38.5|
|                              | Imipenem       | 32           | 32                       | 32                       | 0   | 0  | 100 |
|                              | Ceftazidime    | 0.5 - 64     | 2                        | 64                       | 84.6| 0  | 15.4|
|                              | Ciprofloxacin  | 0.12 - 8     | 1                        | 8                        | 53.8| 7.7 | 38.5|
|                              | Tobramycin     | 4 - 32       | 32                       | 32                       | 30.8| 15.4| 53.8|
|                              | Gentamicin     | 2 - 32       | 32                       | 32                       | 15.4| 23.1| 61.5|
|                              | Ticarcillin-clavulanate | 4 - 128 | 8                        | 64                       | 76.9| 15.4| 7.7 |
|                              | Ceftriaxone    | 16 - 128     | 128                      | 128                      | 0   | 30.8| 69.2|
|                              | Cefotaxime     | 2 - 128      | 32                       | 128                      | 15.4| 46.2| 38.5|
|                              | Cefoxitin      | 64           | 64                       | 64                       | 0   | 0  | 100 |
| *Haemophilus influenzae* (27) | Piperacillin/tazobactam | 0.25 - 0.25 | 0.25                    | 0.25                     | 100 | 0  | 0   |
|                              | Piperacillin   | 0.25 - 0.64  | 0.25                     | 2                        | 88.9| 0  | 11.1|
|                              | Imipenem       | 0.12 - 0.25  | 0.12                     | 0.25                     | 100 | 0  | 0   |
|                              | Ceftazidime    | 0.25 - 0.25  | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Ciprofloxacin  | 0.12 - 0.12  | 0.12                     | 0.12                     | 100 | 0  | 0   |
|                              | Ticarcillin-clavulanate | 0.25 - 0.5 | 0.25                    | 0.25                     | 100 | 0  | 0   |
|                              | Ceftriaxone    | 0.25 - 0.25  | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Cefotaxime     | 0.25 - 0.25  | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Cefoxitin      | 0.25 - 2     | 1                        | 2                        | 100 | 0  | 0   |
| Other Gram-negative rods (7) | Piperacillin/tazobactam | 0.25 - 16 | 0.5                      | 16                       | 100 | 0  | 0   |
|                              | Piperacillin   | 0.25 - 64    | 1                        | 64                       | 71.4| 28.6| 0   |
|                              | Imipenem       | 0.12 - 0.5   | 0.12                     | 0.5                      | 100 | 0  | 0   |
|                              | Ceftazidime    | 0.25 - 16    | 0.5                      | 16                       | 85.7| 14.3| 0   |

Continued on next page
### TABLE 2 continued
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates

| Organism (number of strains) | Antibiotic                | Range (mg/L) | MIC\(_{50}\) (mg/L) | MIC\(_{90}\) (mg/L) | % S  | % I  | % R  |
|------------------------------|---------------------------|--------------|----------------------|---------------------|------|------|------|
| Other Gram-negative rods (7) | Ciprofloxacin             | 0.12 - 0.5   | 0.12                 | 0.5                 | 100  | 0    | 0    |
|                              | Tobramycin                | 0.12 - 16    | 2                    | 16                  | 71.4 | 0    | 28.6 |
|                              | Gentamicin                | 0.12 - 16    | 1                    | 16                  | 71.4 | 0    | 28.6 |
|                              | Ticarcillin-clavulanate   | 0.25 - 32    | 0.25                 | 32                  | 85.7 | 0    | 14.3 |
|                              | Ceftriaxone               | 0.25 - 8     | 0.25                 | 8                   | 100  | 0    | 0    |
|                              | Cefotaxime                | 0.25 - 8     | 0.25                 | 8                   | 100  | 0    | 0    |
|                              | Cefoxitin                 | 0.25 - 64    | 8                    | 64                  | 57.1 | 0    | 42.9 |
| Enterococcus faecalis (124) | Piperacillin/tazobactam   | 0.25 - 32    | 2                    | 4                   | 96.8 | 0    | 3.2  |
|                              | Piperacillin              | 0.25 - 32    | 2                    | 8                   | 92.7 | 0    | 7.3  |
|                              | Imipenem                  | 0.25 - 32    | 1                    | 2                   | 96   | 0.8  | 3.2  |
|                              | Ciprofloxacin             | 0.12 - 8     | 0.5                  | 8                   | 72.6 | 0    | 25   |
|                              | Ticarcillin-clavulanate   | 0.5 - 64     | 16                   | 32                  | 27.4 | 0    | 72.6 |
|                              | Vancomycin                | 0.25 - 64    | 1                    | 1                   | 97.6 | 0    | 2.4  |
| Enterococcus faecium (29) | Piperacillin/tazobactam   | 0.25 - 32    | 32                   | 32                  | 34.5 | 0    | 65.5 |
|                              | Piperacillin              | 0.25 - 32    | 32                   | 32                  | 37.9 | 0    | 62.1 |
|                              | Imipenem                  | 0.25 - 32    | 32                   | 32                  | 37.9 | 0    | 62.1 |
|                              | Ciprofloxacin             | 0.12 - 8     | 8                    | 8                   | 31   | 6.9  | 62.1 |
|                              | Ticarcillin-clavulanate   | 0.25 - 64    | 64                   | 64                  | 24.1 | 0    | 75.9 |
|                              | Vancomycin                | 0.25 - 6     | 0.5                  | 2                   | 99.1 | 0    | 6.9  |
| Other enterococci (7)       | Piperacillin/tazobactam   | 1 - 8        | 1                    | 8                   | 100  | 0    | 0    |
|                              | Piperacillin              | 1 - 8        | 4                    | 8                   | 100  | 0    | 0    |
|                              | Imipenem                  | 0.5 - 32     | 0.5                  | 32                  | 85.7 | 0    | 14.3 |
|                              | Ciprofloxacin             | 0.12 - 4     | 0.5                  | 4                   | 85.7 | 0    | 14.3 |
|                              | Ticarcillin-clavulanate   | 8 - 64       | 16                   | 64                  | 28.6 | 0    | 71.4 |
|                              | Vancomycin                | 0.5 - 2      | 0.5                  | 2                   | 100  | 0    | 0    |
| Staphylococcus aureus (492) | Piperacillin/tazobactam   | 0.25 - 32    | 0.5                  | 1                   | 99.2 | 0    | 0.8  |
|                              | Piperacillin              | 0.25 - 32    | 2                    | 16                  | 88   | 0    | 12   |
|                              | Imipenem                  | 0.12 - 16    | 0.25                 | 0.25                | 99.8 | 0    | 0.2  |
|                              | Cefazidime                | 0.25 - 64    | 4                    | 8                   | 92.1 | 2.6  | 5.3  |
|                              | Ciprofloxacin             | 0.12 - 8     | 0.12                 | 0.25                | 95.9 | 0.4  | 3.7  |
|                              | Ticarcillin-clavulanate   | 0.25 - 128   | 1                    | 4                   | 94.3 | 0    | 5.7  |
|                              | Ceftriaxone               | 0.25 - 128   | 2                    | 4                   | 96.7 | 2.4  | 0.8  |
|                              | Oxacillin                 | 0.12 - 8     | 0.12                 | 0.5                 | 97.6 | 0    | 2.4  |
|                              | Vancomycin                | 0.25 - 64    | 0.5                  | 0.5                 | 99.8 | 0    | 0.2  |
|                              | Clindamycin               | 0.12 - 16    | 0.25                 | 0.5                 | 90.4 | 1.4  | 8.1  |
|                              | Cefuroxime                | 0.25 - 64    | 1                    | 1                   | 97   | 1    | 2    |
|                              | Cefazolin                 | 0.25 - 64    | 0.25                 | 1                   | 98.6 | 0.8  | 0.6  |
| Coagulase-negative staphylococci (104) | Piperacillin/tazobactam | 0.25 - 32    | 0.5                  | 8                   | 91.3 | 0    | 8.7  |
|                              | Piperacillin              | 0.25 - 32    | 2                    | 32                  | 86.5 | 0    | 13.5 |
|                              | Imipenem                  | 0.25 - 32    | 0.25                 | 2                   | 93.3 | 0    | 6.7  |
|                              | Cefazidime                | 0.25 - 64    | 8                    | 64                  | 66.3 | 8.7  | 25   |

Continued on next page
TABLE 2 continued
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates

| Organism (number of strains) | Antibiotic               | Range (mg/L) | MIC<sub>50</sub> (mg/L) | MIC<sub>90</sub> (mg/L) | % S | % I | % R |
|------------------------------|--------------------------|--------------|--------------------------|--------------------------|-----|----|-----|
| Coagulase-negative staphylococci | Ciprofloxacin            | 0.12 - 8     | 0.25                     | 8                        | 60.6| 6.7| 32.7|
|                              | Ticarcillin-clavulanate  | 0.25 - 128   | 0.5                      | 32                       | 80.8| 0  | 19.2|
|                              | Ceftriaxone              | 0.25 - 128   | 4                        | 64                       | 81.7| 6.7| 11.5|
|                              | Oxacillin                | 0.12 - 8     | 2                        | 8                        | 54.8| 0  | 45.2|
|                              | Vancomycin               | 0.25 - 2     | 0.5                      | 1                        | 100 | 0  | 0   |
|                              | Clindamycin              | 0.25 - 16    | 16                       | 16                       | 42.3| 3.8| 53.8|
|                              | Cefuroxime               | 0.25 - 64    | 0.5                      | 64                       | 84.6| 1.9| 13.5|
|                              | Cefazolin                | 0.25 - 64    | 0.5                      | 16                       | 84.6| 6.7| 8.7 |
| Streptococcus pyogenes (54)  | Piperacillin/tazobactam  | 0.25 - 0.5   | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Piperacillin              | 0.25 - 0.25  | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Imipenem                 | 0.25 - 0.5   | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Cefazidime               | 0.25 - 0.5   | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Ciprofloxacin            | 0.12 - 1     | 0.25                     | 0.5                      | 100 | 0  | 0   |
|                              | Ticarcillin-clavulanate  | 0.25 - 0.25  | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Ceftriaxone              | 0.25 - 0.25  | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Oxacillin                | 0.25 - 0.25  | 0.12                     | 0.12                     | 100 | 0  | 0   |
|                              | Vancomycin               | 0.25 - 0.5   | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Clindamycin              | 0.25 - 1     | 0.25                     | 0.25                     | 98.1| 0  | 1.9 |
|                              | Cefuroxime               | 0.25 - 0.5   | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Cefazolin                | 0.25 - 0.25  | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Ampicillin               | 0.06 - 0.25  | 0.06                     | 0.06                     | 100 | 0  | 0   |
| Streptococcus agalactiae (81) | Piperacillin/tazobactam  | 0.25 - 0.25  | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Piperacillin              | 0.25 - 16    | 0.25                     | 0.25                     | 98.8| 0  | 1.2 |
|                              | Imipenem                 | 0.25 - 0.25  | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Cefazidime               | 0.25 - 2     | 0.25                     | 0.5                      | 95.1| 2.5| 2.5 |
|                              | Ciprofloxacin            | 0.12 - 1     | 0.25                     | 0.5                      | 100 | 0  | 0   |
|                              | Ticarcillin-clavulanate  | 0.25 - 4     | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Ceftriaxone              | 0.25 - 1     | 0.25                     | 0.25                     | 98.8| 1.2| 0   |
|                              | Oxacillin                | 0.12 - 1     | 0.12                     | 0.12                     | 100 | 0  | 0   |
|                              | Vancomycin               | 0.25 - 1     | 0.25                     | 0.5                      | 100 | 0  | 0   |
|                              | Clindamycin              | 0.25 - 2     | 0.25                     | 0.25                     | 92.5| 5  | 2.5 |
|                              | Cefuroxime               | 0.25 - 2     | 0.25                     | 0.25                     | 100 | 0  | 0   |
|                              | Ampicillin               | 0.06 - 0.25  | 0.06                     | 0.06                     | 100 | 0  | 0   |
|                              | Cefazolin                | 0.25 - 4     | 0.25                     | 0.25                     | 100 | 0  | 0   |
| Streptococcus pneumoniae (361) | Piperacillin/tazobactam  | 0.12 - 2     | 0.12                     | 0.12                     | 100 | 0  | 0   |
|                              | Piperacillin              | 0.12 - 8     | 0.12                     | 0.12                     | 100 | 0  | 0   |
|                              | Imipenem                 | 0.12 - 0.5   | 0.12                     | 0.12                     | 99.4| 0  | 0.6 |
|                              | Cefazidime               | 0.12 - 16    | 0.12                     | 0.5                      | 90.5| 2.2| 6.9 |
|                              | Ciprofloxacin            | 0.06 - 8     | 0.5                      | 2                        | 88.6| 8.9| 2.5 |
|                              | Ticarcillin-clavulanate  | 0.12 - 16    | 0.12                     | 0.25                     | 96.7| 0  | 3.3 |

Continued on next page
TABLE 2 continued
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates

| Organism (number of strains) | Antibiotic | Range (mg/L) | MIC$_{50}$ (mg/L) | MIC$_{90}$ (mg/L) | % S | % I | % R |
|-----------------------------|------------|--------------|------------------|------------------|-----|----|-----|
| *S pneumoniae*              | Ceftriaxone| 0.12 - 8     | 0.12             | 0.12             | 96.4| 2.8| 0.8 |
|                             | Vancomycin | 0.12 - 2     | 0.12             | 0.5              | 99.7| 0  | 0.3*|
|                             | Clindamycin| 0.12 - 16    | 0.12             | 0.12             | 98.6| 0.3| 1.1 |
|                             | Cefuroxime | 0.12 - 4     | 0.12             | 0.12             | 93.6| 1.4| 5   |
|                             | Cefazolin  | 0.12 - 4     | 0.12             | 0.12             | 100 | 0  | 0   |
|                             | Ampicillin | 0.03 - 4     | 0.03             | 0.12             | 93.3| 0  | 7.0 |

| Viridans streptococci (40) | Piperacillin/tazobactam | 0.25 - 4 | 0.25 | 1.0 | 100 | 0 | 0 |
|                           | Piperacillin             | 0.25 - 8 | 0.25 | 1.0 | 100 | 0 | 0 |
|                           | Imipenem                 | 0.25 - 1 | 0.25 | 0.25| 100 | 0 | 0 |
|                           | Ceftazidime              | 0.25 - 32| 0.5  | 4   | 55  | 15| 30 |
|                           | Ciprofloxacin            | 0.12 - 4 | 0.5  | 2   | 82.5| 15| 2.5 |
|                           | Ticarcillin-clavulanate  | 0.25 - 32| 0.25 | 8   | 90  | 0 | 10 |
|                           | Ceftriaxone              | 0.25 - 2 | 0.25 | 1   | 87.5| 10| 2.5 |
|                           | Vancomycin               | 0.25 - 0.5| 0.25 | 0.5 | 100 | 0 | 0 |
|                           | Clindamycin              | 0.25 - 0.25| 0.25 | 0.25| 100 | 0 | 0 |
|                           | Cefuroxime               | 0.25 - 4 | 0.25 | 2   | 100 | 0 | 0 |
|                           | Cefazolin                | 0.25 - 32| 0.25 | 4   | 92.5| 5 | 2.5 |
|                           | Ampicillin               | 0.06 - 4 | 0.06 | 1   | 85  | 0 | 15 |

| Other streptococci (31) | Piperacillin/tazobactam | 0.25 - 2 | 0.25 | 0.25| 100 | 0 | 0 |
|                        | Piperacillin             | 0.25 - 2 | 0.25 | 0.5 | 100 | 0 | 0 |
|                        | Imipenem                 | 0.25 - 0.5| 0.25 | 0.25| 100 | 0 | 0 |
|                        | Ceftazidime              | 0.25 - 64 | 0.25 | 2   | 87.1| 0 | 12.9 |
|                        | Ciprofloxacin            | 0.12 - 1 | 0.25 | 0.5 | 100 | 0 | 0 |
|                        | Ticarcillin-clavulanate  | 0.25 - 64 | 0.25 | 0.25| 96.8| 0 | 3.2 |
|                        | Ceftriaxone              | 0.25 - 32| 0.25 | 0.25| 90.3| 3.2| 6.5 |
|                        | Vancomycin               | 0.25 - 1 | 0.25 | 0.5 | 100 | 0 | 0 |
|                        | Clindamycin              | 0.25 - 16| 0.25 | 0.25| 90.3| 3.2| 6.5 |
|                        | Cefuroxime               | 0.25 - 8 | 0.25 | 0.25| 100 | 0 | 0 |
|                        | Cefazolin                | 0.25 - 16| 0.25 | 0.25| 93.5| 6.5| 0  |
|                        | Ampicillin               | 0.06 - 4 | 0.06 | 0.12| 93.5| 0 | 6.5 |

% Intermediate; MIC$_{50}$ Minimum inhibitory concentration required to inhibit 50% of isolates; MIC$_{90}$ Minimum inhibitory concentration required to inhibit 90% of isolates; R Resistant; S Susceptible

strains were susceptible to ciprofloxacin. Canadian strains remain highly susceptible to aminoglycosides, the MIC$_{90}$ for tobramycin being only 1 mg/L. Twenty-five strains of *Acinetobacter* species were tested and 96% of these were susceptible to piperacillin/tazobactam compared with only 76% of strains susceptible to piperacillin. Only 76% of strains were susceptible to aminoglycosides, and only 68% were susceptible to ceftriaxone. Ceftazidime was somewhat more active than ceftriaxone (MIC$_{90}$ 8 mg/L versus 64 mg/L) against *Acinetobacter* species.

All 361 strains of *S pneumoniae* were susceptible to piperacillin/tazobactam, piperacillin and imipenem. The highest observed piperacillin/tazobactam MIC was 1 mg/L. The highest imipenem MIC was 0.25 mg/L. Only two ceftriaxone-resistant strains (MIC 2 mg/L or greater) were identified. The highest ceftriaxone MIC observed was 8 mg/L. Of the *S pneumoniae* strains tested, 11.3% had decreased susceptibility to ciprofloxacin (MIC 2 mg/L or greater).

Only three vancomycin-resistant *E faecalis* strains were identified, and only two of 29 *Enterococcus faecium* strains
were vancomycin resistant. While piperacillin/tazobactam was highly active against *E. faecalis*, only 34.5% of *E. faecium* strains were susceptible.

**DISCUSSION**

The antibiotic armamentarium offers a number of choices for the initial empirical treatment of severely ill patients with bacteremia. The choice of agents in this setting should take into account the observed susceptibility patterns of isolates most frequently encountered. In this study, we compared the activity of a number of broad spectrum antibiotics with Canadian strains collected from both tertiary centres, and community and regional hospitals. With the exception of anaerobes and methicillin-resistant staphylococci, the numbers and proportion of strains tested should be quite representative of the Canadian experience. We have previously made the observation that Canadian strains are often more susceptible to antibiotics than those in Europe and the United States, and, therefore, it is important to use Canadian susceptibility data when making therapeutic choices (18).

Of the agents tested, piperacillin/tazobactam and imipenem had the broadest spectrums of activity. We would also expect these agents to be active against the anaerobes that were recovered during the same period of time but were not tested (19). Of the strains tested, only *E. faecium* and *Stenotrophomonas maltophilia* were frequently resistant to these agents – *E. faecium*, by virtue of altered penicillin binding proteins and *S. maltophilia* because of its broad spectrum metalloenzyme and decreased permeability.

Piperacillin/tazobactam was much more active against *E. coli* than piperacillin (MIC of 1 mg/L versus 128 mg/L). Twenty-two per cent more strains were susceptible to piperacillin/tazobactam than to piperacillin alone. This presumably reflects the prevalence of TEM1 beta-lactamases in *E. coli* and their susceptibility to tazobactam (1). For all *Enterobacteriaceae* species tested, the MIC of tazobactam was lower for piperacillin/tazobactam than for piperacillin. Possibly, this represents a small amount of intrinsic activity of tazobactam, as well as its activity against beta-lactamaes from a number of classes. We also observed that *E. cloacae* strains usually had lower MICs to piperacillin/tazobactam than to piperacillin. This has been observed by others and is likely a reflection of the weak activity of tazobactam against class I beta-lactamases (20). When piperacillin/tazobactam was compared with ticarcillin-clavulanate, only *S. maltophilia* was more susceptible to ticarcillin-clavulanate (MIC of 64 mg/L versus 256 mg/L). This has been noted by others (21-24).

A number of agents showed reduced activity against *Acinetobacter* species. Only 76% of strains were susceptible to gentamicin and tobramycin, and only 71% were susceptible to cefotaxime. Imipenem remained highly active against *Acinetobacter* species, the MIC being 0.5 mg/L. Ninety-six per cent of strains were susceptible to imipenem. Piperacillin/tazobactam was more active than piperacillin (MIC of 8 mg/L versus 256 mg/L), and 20% more strains were more susceptible to piperacillin/tazobactam. These findings likely reflect both the intrinsic
activity of tazobactam against Acinetobacter species and the prevalence of beta-lactamases in Acinetobacter species (1,25).

CONCLUSIONS

Blood culture isolates from this Canada-wide study remain highly susceptible to a variety of commonly used antibiotics representing several different classes. Piperacillin and tazobactam together inhibited more than 98% of most organism groups tested, including Enterobacteriaceae species, P aeruginosa, H influenzae and streptococci. Piperacillin/tazobactam has a spectrum of activity that provides coverage for bloodstream infections in the vast majority of cases. Other factors, including the result of treatment trials, pharmacokinetics and pharmacoeconomics, will ultimately be required to define the place of piperacillin/tazobactam in the empirical treatment of suspected bacteremia.

REFERENCES

1. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
2. Bryson HM, Brogden RN. Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-35.
3. Sanders WE, Sanders CC. Piperacillin-tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis 1996;22:107-23.
4. Shlaes DM, Baughman R, Boylen CT, et al. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection. J Antimicrob Chemother 1994;35:665-77.
5. Sweet RL, Roy S, Faro S, O’Brien WF, Sanfilippo IS, Seidlin M. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet Gynecol 1995;83:280-8.
6. Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multi-centre study of piperacillin/tazobactam versus ticarcillin/clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Antimicrob Agents Chemother 1995;39:1211-33.
7. Moulton Y, Leroy O, Beuscart C. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1990;25:199-208.
8. Gorbatch SL. Piperacillin/tazobactam in the treatment of polymicrobial infections. Intensive Care Med 1994;20:527-34.
9. Nowe P. Piperacillin/tazobactam in complicated urinary tract infections. Intensive Care Med 1994;20(Suppl 3):S39-42.
10. Brismar D, Malmborg AS, Tunevall G, et al. Piperacillin/tazobactam versus imipenem-clavulanic acid in the treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-74.
11. Niinikoski J, Havia T, Alhava E et al. Piperacillin/tazobactam versus imipenem/clavulanic acid in the treatment of intra-abdominal infection. Surg Gynecol Obstet 1995;176:255-61.
12. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus cefazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995;39:445-52.
13. Micoczi A, Nucci M, Venditti M, et al. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/ticlopiplan in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 1993;12:1-8.
14. Wise R. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteremia. J Antimicrob Chemother 1993;31(Suppl A):97-104.
15. Charbonneau P. Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy. Intensive Care Med 1994;20:S43-8.
16. National Committee for Clinical Laboratory Standards (NCCLS) methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. approved standard M7-A5. Villanova, 1993.
17. National Committee for Clinical Laboratory Standards (NCCLS) Performance standards for antimicrobial susceptibility testing: 5th informational Supplement, M100-SS. Villanova, 1994.
18. Forward KR, Low DE, Lavriere M, et al. Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates. Can J Infect Dis 1997;8:147-53.
19. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 1993;32:223-31.
20. Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inductively and constitutively expressed Class I beta-lactamases. J Antimicrob Chemother 1990;25:591-9.
21. Knapp CC, Sierra-Madero J, Washington JA. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298, 741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Diagn Microbiol Infect Dis 1989;12:511-5.
22. Fass RJ, Prior RB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother 1989;33:1268-74.
23. Ellipoulos GM, Klim K, Ferraro MJ, Jacoby GA, Moellerin RC Jr. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis 1989;12:481-8.
24. Garcia-Rodriguez JA, Garcia Sanchez JE, Garcia Garcia MI, Garcia Sanchez E, Munoz Bellido JL. Antibiotic susceptibility profile of Xanthomonas maltophilia in vitro activity of -lactam/ -lactamase inhibitor combinations. Diagn Microbiol Infect Dis 1991;14:239-43.
25. Suh B, Shapiro T, Jones R, Satishchandran V, Truant AL. In vitro activity of -lactamase inhibitors against clinical isolates of Acinetobacter species. Diagn Microbiol Infect Dis 1995;21:111-4.
Submit your manuscripts at http://www.hindawi.com